ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2928

STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis

Debomita Chakraborty1, Barbora Šumová2, Tatjana Mallano3, Chih-Wei Chen3, Alfiya Distler3, Christina Bergmann3, Andreas Ramming4, Oliver Distler5, Georg Schett3, Ladislav Senolt6 and Jörg Distler3, 1Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 2Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 6Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Animal models, Fibroblasts, signal transduction, systemic sclerosis and transforming growth factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 8, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that regulates key cellular processes such as proliferation, apoptosis, invasion, angiogenesis, metastasis and immune responses. STAT3 can be phosphorylated and activated by various kinases, several of which have been implicated in aberrant fibroblast activation in fibrotic diseases including systemic sclerosis (SSc). We hypothesized that profibrotic signals converge on STAT3 and that STAT3 may be an important molecular checkpoint for tissue fibrosis.

Methods:  Activation of STAT3, JAK1, JAK2, SRC, c-ABL and JNK was analyzed in SSc patients and in experimental models of SSc by real-time PCR, Western Blot and immunohistochemistry. Selective inhibitors in conjunction with knockdown and knockout strategies were used to target STAT3 signaling and its upstream kinases in vitro and in vivo. The anti-fibrotic potential of genetic and pharmaceutical inactivation of STAT3 was evaluated in two mouse models of SSc: bleomycin-induced fibrosis and fibrosis induced by overexpression of a constitutively active TGFβ receptor type I (TBRact).

Results:  Accumulation of phosphorylated and thus active STAT3 (P-STAT3) was detected in fibroblasts in the skin of SSc patients as compared to healthy volunteers. Enhanced STAT3 signaling was also found in murine models of SSc. The upregulation of P-STAT3 was found to be mediated by TGFβ signaling. Expression profiling and functional studies in vitro and in vivodemonstrated that the activation of STAT3 is mediated by the combined action of JAK, SRC, c-ABL and JNK kinases. STAT3-deficient fibroblasts were less sensitive to the pro-fibrotic effects of TGFβ. Fibroblast-specific knockout of STAT3 also ameliorated experimental fibrosis. In the model of bleomycin-induced fibrosis, dermal thickening was decreased by 77%, collagen content by 52% and myofibroblast counts by 58% compared to compared to littermates with normal expression of STAT3. STAT3 knockout mice were also protected from TBRact-induced fibrosis. Pharmacological inhibition of STAT3 using the small molecule inhibitor S3I-201 exerted potent anti-fibrotic effects and inhibited TGFβ-induced fibroblast activation, bleomycin- and TBRact-induced experimental fibrosis in pharmacologically relevant and well tolerated doses.

Conclusion:  We demonstrate that STAT3 integrates several profibrotic signals in SSc and might thus be a novel core mediator of fibrosis. Inhibition of STAT3 prevented fibroblast activation and demonstrated potent anti-fibrotic effect in different preclinical models of SSc. Considering the potent anti-fibrotic effects observed in this study and the fact that several STAT3 inhibitors are currently tested in clinical trials, STAT3 might be an interesting candidate for molecular targeted therapies of SSc.


Disclosure: D. Chakraborty, None; B. Šumová, None; T. Mallano, None; C. W. Chen, None; A. Distler, None; C. Bergmann, None; A. Ramming, None; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2; G. Schett, None; L. Senolt, None; J. Distler, 4D Science, 1,Anamar Medical, Active Biotech, Array Biopma, BMS, Bayer Pharma, Boehringer Ingelheim, Celgene, GSK, Novartis, Sanofi-Aventis, UCB, 2,Actelion Pharmaceuticals US, Active Biotech, Anamar, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, JB Therapeutics, Medac, Pfizer, RuiYi, UCB, 5.

To cite this abstract in AMA style:

Chakraborty D, Šumová B, Mallano T, Chen CW, Distler A, Bergmann C, Ramming A, Distler O, Schett G, Senolt L, Distler J. STAT3 As an Important Integrator of Profibrotic Pathways in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/stat3-as-an-important-integrator-of-profibrotic-pathways-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/stat3-as-an-important-integrator-of-profibrotic-pathways-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology